Increlex And Galzin Acquisitions Will Broaden Treatment Options
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
16 May 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$29.67
41.6% undervalued intrinsic discount08 Aug
US$17.32
1Y
359.4%7D
17.6%